Company / Operating Cash Flow
Cullinan Therapeutics, Inc. Operating Cash Flow History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$145.3M
FY2024
5-year range
-$145.3M / -$29.8M
FY2020-FY2024
Trend
-8.2%
vs FY2023
Sector context
#148 of 216
Health Care
What the data says
At -$145M, Cullinan Therapeutics, Inc.'s operating cash flow ranks #148 of 216 in the Health Care sector. Operating Cash Flow has declined for 3 consecutive years, from -$30M in FY2021 to -$145M in FY2024.
Based on SEC 10-K filings.
-$145M in FY2024.
Declined from -$127M to -$145M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#148 of 216 in Health CareTop 69% of 216This company -$145.3M Sector average $659.0M
▼
-122.1% below sector average
Key checks
Key Insights
- Cullinan Therapeutics, Inc.'s operating cash flow has declined for 3 consecutive years.
- In FY2024, operating cash flow decreased 8.2% year-over-year.
- Ranks #148 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.33 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$145.3M | -8.2% |
| FY2023 | -$134.3M | -6.0% |
| FY2022 | -$126.7M | -325.4% |
| FY2021 | -$29.8M | +0.0% |
| FY2020 | -$29.8M | - |
As of FY2024 · SEC 10-K · Updated Jul 2, 2026